Aldesleukin Withdrawn Phase 1 Trials for Recurrent Plasma Cell Myeloma / NY-ESO-1 Positive Tumor Cells Present / Refractory Plasma Cell Myeloma / HLA-A*0201 Positive Cells Present Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT03506802TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma